Short Bowel SyndromePhase 3EASE SBS 2NCT03905707
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
A Phase 3 study testing glepaglutide in people with Short Bowel Syndrome, run by Zealand Pharma at 27 sites in 9 countries.
Trial summary
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Short Bowel Syndrome
- What is being tested?
- glepaglutide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 27 sitesin 9 countries
- Study dates
- 7 May 2019to 30 Apr 2026
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Informed consent obtained before any trial-related activity
- Completed the lead-in trial (ZP1848-17111) or completed the Phase 2 trial (ZP1848-15073)
Who cannot join
- Withdrawal of consent from the lead-in trial
- Any condition or disease or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or interfere with the analysis of the trial results
- Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3 months prior to Screening
- Females of childbearing potential, who are pregnant, breast-feeding, intend to become pregnant or are not using highly effective contraceptive methods
Trial locations and contacts
27 sites in 9 countries.
27 sites in 9 countries
United States7 sites
University of Chicago Children's Hospital
Chicago, Illinois, 60637
Cleveland Clinic
Cleveland, Ohio, 44195
Vanderbilt University Medical Center, Nashville
Nashville, Tennessee, 68198-3285
Mount Sinai Hospital
New York, New York, 10029
University of Nebraska Medical Center
Omaha, Nebraska, 68198-3285
Mayo Clinic College of Medicine
Rochester, Minnesota, 55905
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Germany5 sites
Charité - Universitätsmedizin Berlin
Berlin
Universitätsklinikum Bonn
Bonn, 53127
Universitätsklinikum Frankfurt - Med. Klinik I
Frankfurt
Asklepios Kliniken Hamburg GmbH
Hamburg
Universitätsmedizin Rostock
Rostock
United Kingdom4 sites
St Mark's Hospital
Harrow
UCLH Foundation NHS Trust
London
University of East Anglia
Norwich
University Hospital Southampton NHS Foundation Trust
Southampton
Canada3 sites
The Royal Alexandra Hospital
Edmonton
Western University
London, N6A 4V2
University Health Network - Toronto General Hospital
Toronto
Poland3 sites
Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi
Lodz
Solumed
Poznan
Szpital Skawina sp. z o.o. im. Stanley Dudricka
Skawina
About this study
Official title: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS).
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Read the detailed description
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)
- Conditions
- Short Bowel Syndrome
- Being tested
- glepaglutide
- Medical subject headings
- Short Bowel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
glepaglutideDrug
Also called ZP1848
Glucagon-Like Peptide-2 (GLP-2) analog
| Study group | Role | What they receive |
|---|---|---|
| Glepaglutide SC injections twice weekly | Experimental | Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly.
In this long term safety study, there is no placebo arm. Receives: Drug: glepaglutide |
| Glepaglutide SC injections once weekly and placebo once weekly | Experimental | Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly.
In this long term safety study, there is no placebo arm. Receives: Drug: glepaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety - Adverse Events
Incidence and type of Adverse Events
Measured: 2 years
Secondary outcomes (15)
Safety - Serious Adverse Events
Incidence and type of Serious Adverse Events
Measured: 2 years
Safety - Adverse Events of Special Interest
Incidence and type of Adverse Events of Special Interest
Measured: 2 years
Safety - Changes in blood pressure from baseline
Changes in systolic and diastolic blood pressure will be reported
Measured: 2 years
Number of patients with clinically significant changes in 12-Lead electrocardiogram (ECG)
Number of patients with clinically significant changes in ECG will be reported
Measured: 2 years
Immunogenicity - Occurrence of anti-drug antibodies
Occurrence of antibodies against glepaglutide
Measured: 2 years
Change in weekly Parenteral Support (PS) volume
Change in weekly PS volume from baseline
Measured: 2 years
Number of patients with 20 percent reduction in PS volume
Achieving at least 20 percent reduction in weekly PS volume from baseline
Measured: 2 years
Days off PS
Achieving 1 or more days per week off PS
Measured: 2 years
Weaned off PS
Reduction in weekly PS volume of 100 percent (weaned off)
Measured: 2 years
Changes in fluid composite effect
Reduction in PS plus reduction in oral fluid intake plus increase in urine volume from baseline
Measured: 2 years
Energy content (lipids)
Change in lipids content (in kcal/L or kjoule/L) of PS from baseline
Measured: 2 years
Energy content (glucose)
Change in glucose content (in kcal/L or kjoule/L) of PS from baseline
Measured: 2 years
Energy content (amino acids)
Change in amino acids content (in kcal/L or kjoule/L) of PS from baseline
Measured: 2 years
Days on PS
Change in number of days on PS per week from baseline
Measured: 2 years
Number of patients with 40 percent change in PS volume per week
Achieving 40 percent in PS volume from baseline
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2019
- Study start7 May 2019
- Primary completion30 Apr 2026
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Short Bowel SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zealand Pharma
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Zealand Pharma, Study director, Zealand Pharma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03905707
- Sponsor's protocol ID
- ZP1848-17127
- Acronym
- EASE SBS 2
- Status last verified
- Sep 2026
- First submitted
- 28 Mar 2019
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
- ClinicalTrials.gov ID
- NCT03905707
- Acronym / sponsor ID
- EASE SBS 2 / ZP1848-17127
- Conditions
- Short Bowel Syndrome
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Zealand PharmaIndustry (pharma, biotech, devices)
- Study start
- 7 May 2019 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 5 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS).
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Detailed description
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Glepaglutide SC injections twice weekly | Experimental | Drug: glepaglutideGlucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly. In this long term safety study, there is no placebo arm. |
| Glepaglutide SC injections once weekly and placebo once weekly | Experimental | Drug: glepaglutideGlucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly. In this long term safety study, there is no placebo arm. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Informed consent obtained before any trial-related activity
- Completed the lead-in trial (ZP1848-17111) or completed the Phase 2 trial (ZP1848-15073)
Key exclusion criteria (4 listed)
- Withdrawal of consent from the lead-in trial
- Any condition or disease or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or interfere with the analysis of the trial results
- Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3 months prior to Screening
- Females of childbearing potential, who are pregnant, breast-feeding, intend to become pregnant or are not using highly effective contraceptive methods
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| glepaglutideAlso: ZP1848Glucagon-Like Peptide-2 (GLP-2) analog | Drug | Glepaglutide SC injections once weekly and placebo once weekly, Glepaglutide SC injections twice weekly |
Primary outcome
Safety - Adverse Events
Time frame: 2 years
Incidence and type of Adverse Events
15 secondary outcomes
Safety - Serious Adverse Events
Time frame: 2 years
Safety - Adverse Events of Special Interest
Time frame: 2 years
Safety - Changes in blood pressure from baseline
Time frame: 2 years
Number of patients with clinically significant changes in 12-Lead electrocardiogram (ECG)
Time frame: 2 years
Immunogenicity - Occurrence of anti-drug antibodies
Time frame: 2 years
Change in weekly Parenteral Support (PS) volume
Time frame: 2 years
Number of patients with 20 percent reduction in PS volume
Time frame: 2 years
Days off PS
Time frame: 2 years
Weaned off PS
Time frame: 2 years
Changes in fluid composite effect
Time frame: 2 years
Energy content (lipids)
Time frame: 2 years
Energy content (glucose)
Time frame: 2 years
Energy content (amino acids)
Time frame: 2 years
Days on PS
Time frame: 2 years
Number of patients with 40 percent change in PS volume per week
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Short Bowel Syndrome
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingPhase 3
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
Short Bowel Syndrome
Not yet recruitingPhase 2
Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).
Enteric Hyperoxaluria
RecruitingPhase 3
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Short Bowel Syndrome
Active, not recruitingObservational study
Registry for Participants With Short Bowel Syndrome
Short Bowel Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zealand Pharma study director
Zealand Pharma
27 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing glepaglutide in people with Short Bowel Syndrome, run by Zealand Pharma at 27 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 27 sites in United States, Germany, United Kingdom, Canada, Poland and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety - Adverse Events (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.